JaLCDOI 10.18926/AMO/56184
フルテキストURL 72_4_431.pdf
著者 Sekimizu, Masahiro| Osumi, Tomoo| Fukano, Reiji| Koga, Yuhki| Kada, Akiko| Saito, Akiko M.| Mori, Tetsuya|
抄録 Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).
キーワード crizotinib recurrent refractory anaplastic large cell lymphoma neuroblastoma
Amo Type Clinical Study Protocol
発行日 2018-08
出版物タイトル Acta Medica Okayama
出版者 Okayama University Medical School
開始ページ 431
終了ページ 436
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
著作権者 CopyrightⒸ 2018 by Okayama University Medical School
論文のバージョン publisher
査読 有り
PubMed ID 30140094